drugset / Trial / NCT00730015

Trial of Linaclotide in Patients With Chronic Constipation

NCT00730015

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each dosing group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder.

Timeline

Start
2008-08
Primary completion
2009-08
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide 145 ug Oral
Subject Linaclotide Peptide 290 ug Oral

Indications